Artículos por temáticas

BDNF prevents NMDA-induced toxicity in models of Huntington's disease: the effects are genotype specific and adenosine A2A receptor is involved.

Martire A, Pepponi R, Domenici MR, Ferrante A, Chiodi V, Popoli P.

J Neurochem. 2013 Apr;125(2):225-35. doi: 10.1111/jnc.12177.

Reduced cancer incidence in Huntington's disease: record linkage study clue to an evolutionary trade-off?

Turner MR, Goldacre R, Goldacre MJ.

Clin Genet. 2013 Jun;83(6):588-90. doi: 10.1111/cge.12010. No abstract available.

Pharmacological upregulation of PGC1α in oligodendrocytes: implications for Huntington's Disease.

Xiang Z, Krainc D.

J Huntingtons Dis. 2013;2(1):101-5. doi: 10.3233/JHD-130046.

Association between caffeine intake and age at onset in Huntington's disease.

Simonin C, Duru C, Salleron J, Hincker P, Charles P, Delval A, Youssov K, Burnouf S, Azulay JP, Verny C, Scherer C, Tranchant C, Goizet C, Debruxelles S, Defebvre L, Sablonnière B, Romon-Rousseaux M,

Neurobiol Dis. 2013 Oct;58:179-82. doi: 10.1016/j.nbd.2013.05.013.

Psychological well-being in persons affected by Huntington's disease: a comparison of at-risk, prodromal, and symptomatic groups.

Chisholm LZ, Flavin KT, Paulsen JS, Ready R.

J Health Psychol. 2013 Mar;18(3):408-18. doi: 10.1177/1359105312444646.

Microtransplantation of whole ganglionic eminence cells ameliorates motor deficit, enlarges the volume of grafts, and prolongs survival in a rat model of Huntington's disease.

Zhu M, Shu K, Wang H, Li X, Xiao Q, Chan W, Emmanuel B, Jiang W, Lei T.

J Neurosci Res. 2013 Dec;91(12):1563-71. doi: 10.1002/jnr.23282.

Usefulness of the Montreal Cognitive Assessment (MoCA) in Huntington's disease.

Gluhm S, Goldstein J, Brown D, Van Liew C, Gilbert PE, Corey-Bloom J.

Mov Disord. 2013 Oct;28(12):1744-7. doi: 10.1002/mds.25578.

Histone Deacetylase 4 (HDAC4) Inhibitors: A Promising Treatment for Huntington's Disease.

Abdel-Magid AF.

ACS Med Chem Lett. 2013 Jun 13;4(8):692-3. doi: 10.1021/ml4002216. No abstract available.

Treatment of psychotic and behavioral symptoms with clozapine, aripiprazole, and reboxetine in a patient with Huntington's disease.

Edlinger M, Seppi K, Fleischhacker W, Hofer A.

Int Clin Psychopharmacol. 2013 Jul;28(4):214-6. doi: 10.1097/YIC.0b013e328361e145.

nNOS(+) striatal neurons, a subpopulation spared in Huntington's Disease, possess functional NMDA receptors but fail to generate mitochondrial ROS in response to an excitotoxic challenge.

Canzoniero LM, Granzotto A, Turetsky DM, Choi DW, Dugan LL, Sensi SL.

Front Physiol. 2013 May 16;4:112. doi: 10.3389/fphys.2013.00112.

Neurodegenerative disease: altered DNA methylation and RNA splicing could be key mechanisms in Huntington disease.

Wood H.

Nat Rev Neurol. 2013 Mar;9(3):119. doi: 10.1038/nrneurol.2013.23. No abstract available.

Pluripotent hybrid stem cells from transgenic Huntington's disease monkey.

Laowtammathron C, Chan AW.

Methods Mol Biol. 2013;1010:61-77. doi: 10.1007/978-1-62703-411-1_5.

Chorea in the clinical presentation of moyamoya disease: results of surgical revascularization and a proposed clinicopathological correlation.

Ahn ES, Scott RM, Robertson RL Jr, Smith ER.

J Neurosurg Pediatr. 2013 Mar;11(3):313-9. doi: 10.3171/2012.11.PEDS12199.

Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the Guideline Development Subcommittee of the American Academy of Neurology.

Suchowersky O, Armstrong MJ, Miyasaki J.

Neurology. 2013 Mar 5;80(10):970. doi: 10.1212/WNL.0b013e3182885eb3. No abstract available.

Relationship of Mediterranean diet and caloric intake to phenoconversion in Huntington disease.

Marder K, Gu Y, Eberly S, Tanner CM, Scarmeas N, Oakes D, Shoulson I; Huntington Study Group PHAROS Investigators..

JAMA Neurol. 2013 Nov;70(11):1382-8. doi: 10.1001/jamaneurol.2013.3487.